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Abstract 
Introduction: Present study examined the frequency of CMV infection during follow-up using 
quantitative nucleic acid amplification testing, the frequency of administration of infection 
prophylaxis, viremia and infection in kidney transplant recipients who underwent transplantation (TX) 
at the University Hospital Center Osijek. 
Materials and Methods: 107 kidney recipients who underwent transplantation in the period 20 
October 2007 – 24 August 2016 were included. Demographic and clinical data, data about pre-
transplantation CMV IgG test results of recipients and their donors, data about CMV prophylaxis, 
viremia, infection, and kidney transplant function were taken from medical records and analyzed. 
Results: 92.5% of kidney recipients and 86% of donors were CMV IgG positive before TX. 28% of 
recipients were CMV-DNA positive at some point after TX, none of whom received a transplant from 
an IgG negative donor. 89.7% of participants received CMV prophylaxis. Seven participants developed 
CMV disease, 2 of whom were not administered prophylaxis. Participants were tested for CMV-DNA 
once a year (median; min 0 max 6). CMV disease was marginally more frequent in those who did not 
receive valganciclovir prophylaxis (P = 0.066). 
Conclusion: It seems wise to enforce the administration of CMV prophylaxis and CMV-DNA testing 
in accordance with protocol, in order to detect viremia on time and to implement preemptive 
treatment, aiming at prevention of clinical manifestation of infection and preservation of graft 
function. 
 
(Šisl D, Zibar L. Cytomegalovirus Infection in Kidney Transplant Recipients. SEEMEDJ 2021; 5(1); 17-24) 
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Introduction 
Cytomegalovirus (CMV) infection is one of the 
most common opportunistic infections in kidney 
transplant recipients. There are two ways of 
acquiring the infection: reactivation of the virus 
or de novo infection of an immunocompromised 
patient. The infection can be asymptomatic, it 
can jeopardize the function of the graft and/or 
cause a systemic infection and even death. 
CMV infection is defined as virus isolation or 
detection of viral proteins (antigens) or nucleic 
acid in any bodily fluid or tissue specimen, 
regardless of symptoms. CMV disease is defined 
as evidence of CMV infection with attributable 
symptoms and can be further categorized as a 
viral syndrome (i.e. fever, malaise, leukopenia, 
and/or thrombocytopenia), or as a tissue-
invasive (“end organ”) disease. 
In recent years, administration of CMV infection 
prophylaxis during the first post-transplantation 
months has become a standard part of therapy 
after kidney transplantation (TX). It is also 
recommended to observe CMV viremia using 
quantitative nucleic acid amplification testing 
(QNAT) that detects CMV-DNA 
(deoxyribonucleic acid). Prophylaxis and 
diagnostics raise the cost of treatment. 
However, modern protocols justify this 
approach with the lower total cost of the 
treatment, since it is deemed that this approach 
leads to fewer complications. 
The prophylaxis and diagnostics protocol at the 
University Hospital Center (UHC) Osijek is not 
strict and has changed in recent years, while the 
approach to prophylaxis and diagnostics is not 
completely uniform. The aim of the study was to 
examine the frequency of CMV infection during 
follow-up using quantitative nucleic acid 
amplification testing (QNAT) for CMV-DNA, the 
frequency of administration of CMV infection 
prophylaxis, and the frequency of CMV viremia 
and infection in kidney transplant recipients who 
received their transplant in UHC Osijek during 
the period between 20 October 2007 and 24 
August 2016. 
Materials and Methods  
The study included 107 participants, 60 men and 
47 women, who underwent kidney TX in UHC 
Osijek in the period between 20 October 2007 
and 24 August 2016. Median age at the time of 
the TX was 51 (min. 27, max. 71), while at the time 
of the study it was 57 (min. 32, max. 74). Research 
methods included collecting data from medical 
records and statistical analysis. The following 
data were analyzed: demographic data of the 
participants (age, sex), clinical features of the 
participants (primary kidney disease, data about 
dialysis and TX), data about CMV IgG test results 
of both recipients and their donors prior to TX, 
data about CMV prophylaxis, viremia, infection, 
and about kidney transplant function. 
Statistical analysis 
Data analysis was conducted using SPSS for 
Windows (version 16.0, SPSS Inc., Chicago, IL, 
USA). Nominal data were expressed as absolute 
and relative frequencies. Numerical data were 
expressed as mean and standard deviation (SD) 
in case of normal distribution, and as median and 
range (min. – max. or interquartile range, IQR) in 
case of asymmetric distribution. The 
Kolmogorov-Smirnov test was used to analyze 
the normality of distribution of the variables. 
Differences in frequencies were tested using the 
chi-square test, in numeric variables of normal 
distribution using Student’s t-test and Mann-
Whitney U test by asymmetric distribution. 
Correlations between numeric variables were 
tested using Spearman’s Rho test. Statistical 
significance was accepted at P < 0.05. 
Results 
For 97 kidney recipients (90.7%) this was the first 
TX, for 7 of them (6.5%) the second, and for 3 of 
them (2.8%) the third one. Table 1 shows the 
demographic data of the participants. Female 
participants were significantly older both at the 
time of the study (Mann-Whitney U test, P = 
0.003) and at the time of the TX (Mann-Whitney 
U test, P = 0.001). By September 2016, 12 (11.2%) 
participants, 6 men and 6 women, had died, one 
of whom was CMV IgG negative before the TX. 
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There was no significant difference in mortality 
between men and women (Mann-Whitney U 
test, P = 0.654). 
Table 1. Demographic data of patients 
Number of patients (%) 
Male Female 
60 (56%) 47 (44%) 
Age (median in 
years) 
At the time of the 
study (IQR) 
53 (45–59) 60 (53–65) 
At the time of the 
TX* (IQR) 
50 (42–54) 55 (49–61) 
*transplantation 
 
Table 2. CMV* serology data 
 N % 
CMV IgG prior 
to TX 
Recipient  
Positive  99 92.5 
Negative  8 7.5 
Donor** 
Positive 92 86 
Negative 14 13.1 
Recipient–donor pairs 
based on CMV serology 
R+/D+ 84 79.2 
R+/D- 14 13.3 
R-/D+ 8 7.5 
R-/D- 0 0 
*cytomegalovirus, **data for one donor were unavailable 
R – recipient, D – donor  
 
 
Table 2 shows the CMV serology data. 
Protocolar administration of CMV prophylaxis 
was introduced in February 2009. Table 3 shows 
data related to prophylaxis administration and 
development of CMV infection and disease. Two 
out of 3 (66.7%) participants who were not 
administered prophylaxis and 5 out of 27 (18.5%) 
of those who were administered prophylaxis 
developed a clinical manifestation of disease, 
with no significant (rather, marginal) difference in 
occurrence (Mann-Whitney U test, P = 0.066). 
Sixteen (53.4%) positive participants were men, 
while 14 (46.6%) were women. No significant 
difference was found in the frequency of CMV-
DNA positivity between the sexes (Mann-






SEEMEDJ 2021, VOL 5, NO. 1 Cytomegalovirus in Kidney Transplantion 
20 Southeastern European Medical Journal, 2021; 5(1) 
 
Table 3. CMV* prophylaxis and infection data 
 N % 
Prophylaxis 
Administered 96 89.7 
Not administered 11 10.3 





















R+/D+ 26 86.7 
R-/D+ 4 13.3 
CMV disease 




Did not receive 
prophylaxis 
2 28.6 
*cytomegalovirus, **positive for CMV-DNA was defined as having > 1000 copies/mL, ***immunoglobulin G, R – 
recipient, D – donor 
 
The group in which the recipient was CMV IgG 
positive and the donor negative was significantly 
less often CMV-DNA positive at some point after 
the TX in comparison with the group in which the 
recipient was CMV IgG negative and the donor 
positive (Mann-Whitney U test, P = 0.002), and in 
comparison with the group in which both were 
CMV IgG positive (Mann-Whitney U test, P = 
0.016). There was no significant difference in the 
frequency of positivity at some point after the TX 
between the group in which both were positive 
and the one in which the recipient was CMV IgG 
negative and the donor positive (Mann-Whitney 
U test, P = 0.159). No recipient of a CMV IgG 
negative donor became CMV-DNA positive. 
There was no pairing in which both the recipient 
and the donor were CMV IgG negative. 
Table 4 shows data related to CMV-DNA testing 
and follow-up. According to the kidney function 
criteria for prophylaxis dosing, the participants 
received the appropriate drug dose. Table 5 
shows graft function data. There was no 
significant difference between the sexes in 
creatinine concentration in the serum at the start 
of administration of prophylaxis (Mann-Whitney 
U test, P = 0.365). The group in which the 
recipient was CMV IgG positive and the donor 
negative had significantly lower serum 
creatinine concentration at the end of 
prophylaxis administration compared to the 
group in which both were CMV IgG positive 
(Mann-Whitney U test, P = 0.009). Women had 
significantly lower serum creatinine 
concentration than men at the end of 
prophylaxis (Mann-Whitney U test, P = 0.002). 
Seven out of 30 participants (23.3%) who were 
CMV-DNA positive at some point after the TX 
developed CMV disease. In 2 of them, it 
manifested as invasive CMV disease, while in the 
other 5 it manifested as a viral syndrome with 
leukopenia, fever, malaise, loss of appetite, 
diarrhea, and weight loss. 
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Table 4. CMV-DNA* testing and follow-up data 
  N 
Number of tests 
performed 
Total  442 
Per patient 
(median + IQR) 
4 (2–6) 
Per patient year 1.03 
Follow up 
duration  
Patient years 426 
median + IQR 4 (2–6) 
 
Min – max 0–9 
*cytomegalovirus deoxyribonucleic acid 
 
Table 5. Graft function data 




Start of prophylaxis –
median (IQR) 
35 (19.5–48.5)  
 N % 
Value 
> 60 14 14.6 
40–59  26 27.1 
25–39  23 24 
10–24  24 25 
< 10 6 6.3 
Unavailable  3 3.1 





Men  187 (127–264) 
Women  152 (119–262) 
End of 
prophylaxis 
Men  129 (111–145) 
Women  103 (93–141) 
R+/D+ 128 (101–148) 
R+/D- 106 (94–110 ) 
R-/D+ 119 (99–166 ) 
*glomerular filtration rate, R – recipient, D – donor  
 
Discussion 
Kidney TX has been performed at the UHC 
Osijek since 2007, and the availability of CMV-
DNA diagnostics dates back to 2009. Before 
2007, patients treated at the UHC Osijek dialysis 
department had their TX at UHC Zagreb, UHC 
Rijeka or Merkur Clinical Hospital, and CMV 
diagnostics was performed in Zagreb or Rijeka. 
This study included only the patients whose TX 
and diagnostics were performed in Osijek. 
CMV is widely present in the population, which 
has been shown in numerous studies, according 
to which the prevalence of seropositivity to CMV 
IgG ranges from 30 to 97% (1, 2). Results of this 
study agree with those results, finding that 92.5% 
of recipients and 86% of their donors were CMV 
IgG positive prior to the TX. This could be 
considered as a high prevalence. 
Since CMV presents a significant risk of 
morbidity and mortality in the population of 
persons who have received transplants, the 
importance of prevention of reactivation or de 
novo infection has been recognized, whether it 
is performed by administering prophylaxis or 
through preemptive treatment (3 – 7, 14). 
Prevention of CMV infection at the UHC Osijek 
started in February 2009 with administration of 
oral valganciclovir, at first during 3 months for 
CMV IgG positive and 6 months for CMV IgG 
negative recipients, and since October 2014, a 
universal 6-month prophylaxis has been in use. 
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Taking that into consideration, 96 of 107 kidney 
recipients, or 89.7%, were administered 
prophylaxis, which is a large share of recipients. 
The standard dose of oral valganciclovir in CMV 
prophylaxis is 900 mg per day. That dose is 
adjusted for renal function, an indicator of which 
is creatinine clearance (or calculated GFR). Dose 
adjustment is extremely important since 
valganciclovir can cause nephrotoxicity and thus 
jeopardize the graft function. Some of the side 
effects of valganciclovir, such as leukopenia, 
nausea, diarrhea, and elevated serum liver 
enzymes, overlap with the symptoms of CMV 
infection and disease, which is why finding the 
actual cause of such symptoms is of great 
importance. 
Regular testing for CMV-DNA plays an important 
role, and it can help with early detection of 
infection and administration of preemptive 
treatment already at low viral loads, which could 
lead to prevention of clinical manifestations and 
better preservation of graft function, since 
preemptive treatment has been linked to fewer 
toxic effects on the transplanted kidney in 
comparison with the prophylaxis (8). CMV 
infection and disease can, however, appear 
despite preventive therapy, and the reasons for 
this are incorrect dosing, discontinuation of 
preventive therapy, or simply a failure of such 
therapy (4). 
Thirty recipients, or 28% of those who were 
included in the study, developed CMV infection 
(and 7 of them had CMV disease), which is a 
relatively high number if we consider the fact 
that most of them took prophylaxis. A primary 
risk factor for the development of CMV viremia 
and disease is considered to be the serostatus of 
the recipient–donor pair regarding CMV IgG 
antibodies; the pairs in which both are positive 
and in which the recipient is negative and the 
donor positive are under increased risk for the 
development of CMV disease (9 – 12). Most of 
the CMV-DNA positive recipients in this study 
come from a recipient–donor pair in which both 
were CMV IgG positive, 26 out of 30 in total, 
which is 86.7% of all positive recipients. The other 
4 CMV-DNA positive participants come from a 
recipient–donor pair in which the recipient was 
CMV-DNA negative and the donor positive. 
Considering the fact that recipient–donor pairs in 
which both were CMV IgG positive far 
outnumbered participants with other serological 
combinations, it is necessary to mention the 
share of CMV-DNA positive participants in each 
group. There were 84 participants belonging to 
a pair in which both the recipient and the donor 
were CMV IgG positive, and out of them all, 26 
were CMV-DNA positive at some point after the 
TX, which constitutes 31% of such participants. 
Seven participants belonged to a recipient–
donor pair in which the recipient was CMV IgG 
negative and the donor positive. Among them, 4 
participants became CMV-DNA positive. The 
remaining 14 participants for whom the 
serostatus combination is known belonged to a 
recipient–donor pair in which the recipient was 
CMV IgG positive and the donor was negative; 
none of them became CMV-DNA positive. There 
were no recipient–donor pairs in which both 
were CMV IgG negative. These findings coincide 
with previous studies from the pre-prophylaxis 
era, which studied the natural course of CMV 
infection in kidney transplant recipients and 
showed that 56% of kidney transplant recipients 
from a recipient–donor pair in which the 
recipient is CMV IgG negative and the donor 
positive develop CMV disease after TX, as do 
20% of those from a pair in which both the 
recipient and the donor are CMV IgG positive (12). 
The participants of this study who received a 
kidney transplant from a CMV IgG negative 
donor (all of them were CMV IgG positive in this 
study), in addition to never becoming CMV-DNA 
positive after the TX, also had better kidney 
transplant function compared to those who 
received their graft from a CMV IgG positive 
donor. Lack of viremia in such participants was 
accompanied by better kidney transplant 
function. There was no significant difference in 
the occurrence of CMV-DNA positivity between 
the participants who took prophylaxis and those 
who did not, but CMV disease was more 
common in those who did not take it, with 
marginal significance (P = 0.066). However, with 
an insufficiently large sample of participants 
who did not take prophylaxis, the rarity of clinical 
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manifestations of infections in relatively 
common viremia could still be interpreted as a 
consequence of administered prophylaxis and 
timely detection of viremia with regular testing 
for CMV-DNA. 
Out of 7 participants who had clinical symptoms, 
2 developed CMV disease and 5 of them had 
CMV syndrome. One participant from the pre-
prophylaxis era developed early invasive CMV 
disease and died as a result. One participant 
developed CMV disease, which manifested in 
elevated serum liver enzymes and esophagitis. 
Of the participants who had CMV syndrome, 1 
participant had elevated serum liver enzymes, 1 
had leukopenia and 1 had weight loss. One 
participant had diarrhea, fever, and malaise, and 
1 had diarrhea and loss of appetite. All of them, 
except for the deceased one, were successfully 
treated with antiviral medication. 
Previous studies have shown that 
gastrointestinal symptoms were the most 
common manifestations of CMV infection and 
disease (3, 13), which coincides with our findings. 
Participants were tested for CMV-DNA once a 
year on average, but the frequency of such 
testing greatly varied from participant to 
participant, with some of them not being tested 
for years during certain periods. Such findings, 
together with the relatively frequent CMV 
viremia in the observed population, and the 
significance which CMV infection has for graft 
function and overall survival of kidney transplant 
recipients, lead us to conclude that more work is 
needed to develop a standardized protocol for 
prevention of CMV infection in kidney transplant 
recipients. 
The limitations of this study, in the sense of 
evidence-based medicine, were the 
epidemiological character (design) and the 
absence of comparable data in a scenario 
without prophylaxis, since diagnostics, 
screening and follow-up of CMV were rare and 
deficient in the pre-prophylaxis era. Other than 
that, there remains an important aspect of this 
problem, which could complement this study in 
the future. It is the immunosuppressive protocol 
that was part of the participants’ treatment, its 
dynamics over time, with respect to both the 
year of TX and the protocols in force during that 
time, as well as complications and comorbidities 
other than CMV. Likewise, the promptness of the 
valganciclovir dose adjustment in relation to 
kidney function dynamics should be studied, 
although it appears adequately adjusted at the 
two studied points of time – at the beginning and 
at the end of administration of prophylaxis. 
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